| |
|
|
Boryung Pharmaceutical (003850) |
|
|
STOCK |
|
|
| Address |
BORYUNG BLDG., 66-21, WONNAM-DONG, JONGNO-GU,SEOUL |
| Home Page |
www.boryung.co.kr
|
| Established |
1963.11.11 |
Tel |
02-708-8000 |
| Listed |
1988.10.24 |
IR |
|
| Common shares O/S |
2,900,000 |
President |
Kim,Seung Ho/Kim,Gwang Ho |
| Preferred shares O/S |
|
No.of Employees |
837(2007. 6) |
| The sales growth is stagnant despite the steady increase of the main products amid the stock restructuring being undertaken. The profitability has slightly improved due to the decreased cost ratio despite the expanded R&D expenses and the restructuring cost. The financial structure is improving as the owner's equity is being inceased while the borrowing going down. |
| The sales will go up with the steady sales of the main products, Synalong, Gelfos amid the intensified operating activities. The profitability improvement will be possible due to the reduced expenses amid the visible result from the restructuring. It has won in the lawsuit in relation to the Oxaliplatin liquid medicine(a medicine for stomache cancer and large instestine cancer) of Sanofi Abentis. It will launch the generic whithin this year. |
|
  |
(date: 2007.06, unit : %) |
| Name |
BORYUNG |
GMO |
Boryung Medience |
| Portion |
18.8 |
11.0 |
9.6 |
|
 |
(unit : %) |
| Sales |
Gelpos M |
8.5 |
Cost |
Raw Materials |
68.1 |
| Cinalong |
8.1 |
Labors |
11.7 |
| Others |
73.6 |
Overhead |
20.1 |
|
 |
(Unit : 100Mn.Won,Won) |
| Year |
00. 4 |
01. 4 |
04. 4 |
06. 4 |
07. 4 |
| Type |
SD |
SD |
SD |
SD |
SD |
| Amount |
3.11 |
3.00 |
3.00 |
3.00 |
3.00 |
|
|
|
|
